FIELD: chemistry.
SUBSTANCE: disclosed compounds have activity and selectivity towards the GABA A receptor subunit α5. In formula I 
, R1 denotes hydrogen, halogen, phenyl, a 6-member heterocycyl with 2 heteroatoms selected from N, O, a 5-member heteroaryl with 1-2 heteroatoms selected from S, N, cyano, lower alkyl, -(CH2)n-C3-C7-cycloalkyl, -(CH2)n-N(R)2, -(CH2)n-O-lower alkyl or -(CH2)n-OH; equals 0, 1 or 2; R denotes hydrogen or lower alkyl; R2 denotes C3-C7-cycloalkyl, phenyl, 5-6-member heteroaryl with 1 heteroatom selected from N, S or a 9-10-member bicyclic heteroaryl with 1-3 heteroatoms selected from N, which are possibly substituted with one or more substitutes selected from a group comprising halogen, cyano, nitro, oxo group, lower alkyl, lower alkyl substituted with a halogen, lower alkoxy, lower alkoxy substituted with a halogen, -C(O)O-lower alkyl, lower alkylsulphonyl, -NRaRb, -C(O)-NRaRb, -C(O)-(6-member heterocyclyl with 2 heteroatoms selected from N, O), benzyloxy, 6-member heterocyclyl with 1-2 heteroatoms selected from N, S, O, possibly substituted with hydroxy, 1-2 oxo-groups, halogen or lower alkyl, or selected from a 5-6-member heteroaryl with 1-3 heteroatoms selected from N, possibly substituted with lower alkyl; Ra and Rb independently denote hydrogen, lower alkylsulphonyl, -C(O)H, -(CH2)n-N(R)2, -(CH2)n-O-lower alkyl, -(CH2)n-S-lower alkyl, -(CH2)n-S(O)2-lower alkyl, (5-member heteroaryl with 1 heteroatom selected from S)-sulphonyl, lower alkyl, -(CH2)n-(5-6-member heterocyclyl with 1 heteroatom selected from O, N), possibly substituted with lower alkyl, oxo group, or denotes -(CH2)n-C3-C7-cycloalkyl, -(CH2)n-(5-6-member heteroaryl with 1-2 heteroatoms selected from N), possibly substituted with an oxo group, -(CH2)n-OH, -(CO)-R', where R' denotes C3-C7-cycloalkyl, a 5-member heteroaryl with 1 heteroatom selected from S, or lower alkyl; R' denotes a phenyl or a 6-member heteroaryl with 1 heteroatom selected from N which are possibly substituted with a halogen or lower alkyl, optionally substituted with a halogen. The invention also relates to a medicinal agent containing one or more compounds of formula I and use of the disclosed compounds to prepare a medicinal agent.
EFFECT: high effectiveness of derivatives.
16 cl, 145 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARYL-ISOXAZOLE-4-YL-IMIDAZOLE DERIVATIVES | 2006 |
|
RU2425045C2 |
| BENZOYLPIPERIDINE DERIVATIVES AS 5HT AND D RECEPTOR MODULATORS | 2007 |
|
RU2396265C2 |
| HETEROARYL-SUBSTITUTED PIPERIDINE DERIVATIVES AS HEPATIC CARNITINE PALMITOYLTRANSFERASE (L-CPT1) INHIBITORS | 2006 |
|
RU2396269C2 |
| PYRIDINE AND PYRIMIDINE DERIVATIVES AS mGluR2 ANTAGONISTS | 2007 |
|
RU2451673C2 |
| SUBSTITUTED BENZIMIDAZOLES AND MEDICINAL AGENT BASED ON THEREOF | 2000 |
|
RU2261248C2 |
| ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-a]PYRIDINE SUITABLE FOR TREATING ALZHEIMER'S DISEASE THROUGH GABA RECEPTORS | 2007 |
|
RU2426732C2 |
| PYRIDINES SUBSTITUTED WITH HETEROARYL AND APPLICATION METHODS | 2017 |
|
RU2756743C2 |
| NITROGEN-CONTAINING HETEROARYL DERIVATIVES | 2011 |
|
RU2559895C2 |
| USING IkB KINASE INHIBITOR IN ANESTHETIZING TREATMENT | 2003 |
|
RU2320338C2 |
| PHARMACEUTICAL COMBINATIONS CONTAINING PYRIDO[4,3-d]PYRIMIDINE DERIVATIVES AS HSP90 INHIBITOR AND HER2 INHIBITOR | 2009 |
|
RU2532375C2 |
